argenx NV ADR (ARGX)vsDermata Therapeutics Inc (DRMA)
ARGX
argenx NV ADR
$1,058.90
+1.13%
HEALTHCARE · Cap: $64.66B
DRMA
Dermata Therapeutics Inc
$1.46
-9.32%
HEALTHCARE · Cap: $5.91M
Smart Verdict
WallStSmart Research — data-driven comparison
ARGX leads profitability with a 32.3% profit margin vs 0.0%. ARGX earns a higher WallStSmart Score of 71/100 (B).
ARGX
Strong Buy71
out of 100
Grade: B
DRMA
Avoid23
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+65.2%
Fair Value
$2398.58
Current Price
$1058.90
$1339.68 discount
Intrinsic value data unavailable for DRMA.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 31 in profit
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 32.0%
Revenue surging 59.3% year-over-year
Earnings expanding 95.2% YoY
Conservative balance sheet, low leverage
Reasonable price relative to book value
Areas to Watch
Expensive relative to growth rate
Premium valuation, high expectations priced in
Weak financial health signals
Trading at 196.8x book value
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : ARGX
The strongest argument for ARGX centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 32.3% and operating margin at 32.0%. Revenue growth of 59.3% demonstrates continued momentum.
Bull Case : DRMA
The strongest argument for DRMA centers on Price/Book.
Bear Case : ARGX
The primary concerns for ARGX are PEG Ratio, P/E Ratio, Piotroski F-Score.
Bear Case : DRMA
The primary concerns for DRMA are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
ARGX profiles as a growth stock while DRMA is a value play — different risk/reward profiles.
DRMA carries more volatility with a beta of 0.66 — expect wider price swings.
ARGX is growing revenue faster at 59.3% — sustainability is the question.
ARGX generates stronger free cash flow (749M), providing more financial flexibility.
Bottom Line
ARGX scores higher overall (71/100 vs 23/100), backed by strong 32.3% margins and 59.3% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
argenx NV ADR
HEALTHCARE · BIOTECHNOLOGY · USA
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
Dermata Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Dermata Therapeutics Inc. is a clinical-stage biotechnology company focused on developing innovative therapies for dermatological conditions, particularly through its lead candidate, DMT310. Utilizing a proprietary delivery system, DMT310 seeks to enhance the efficacy of existing acne treatments while addressing significant unmet needs within the dermatology space. With a robust pipeline and a commitment to pioneering dermatological solutions, Dermata Therapeutics is positioned to make a meaningful impact on skin health and improve patient outcomes. As the company advances in its clinical trials, it holds the potential to become a disruptive player in the treatment of skin disorders.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?